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Abstract
Objective To derive and validate an algorithm to estimate the absolute
risk of having ovarian cancer in women with and without symptoms.
Design Cohort study with data from 375 UK QResearch general practices
for development and 189 for validation.
Participants Women aged 30-84 without a diagnosis of ovarian cancer
at baseline and without appetite loss, weight loss, abdominal pain,
abdominal distension, rectal bleeding, or postmenopausal bleeding
recorded in previous 12 months.
Main outcome The primary outcome was incident diagnosis of ovarian
cancer recorded in the next two years.
Methods Risk factors examined included age, family history of ovarian
cancer, previous cancers other than ovarian, body mass index (BMI),
smoking, alcohol, deprivation, loss of appetite, weight loss, abdominal
pain, abdominal distension, rectal bleeding, postmenopausal bleeding,
urinary frequency, diarrhoea, constipation, tiredness, and anaemia. Cox
proportional hazards models were used to develop the risk equation.
Measures of calibration and discrimination assessed performance in the
validation cohort.
Results In the derivation cohort there were 976 incident cases of ovarian
cancer from 2.03 million person years. Independent predictors were age,
family history of ovarian cancer (9.8-fold higher risk), anaemia (2.3-fold
higher), abdominal pain (sevenfold higher), abdominal distension (23-fold
higher), rectal bleeding (twofold higher), postmenopausal bleeding
(6.6-fold higher), appetite loss (5.2-fold higher), and weight loss (twofold
higher). On validation, the algorithm explained 57.6% of the variation.
The receiver operating characteristics curve (ROC) statistic was 0.84,
and the D statistic was 2.38. The 10% of women with the highest
predicted risks contained 63% of all ovarian cancers diagnosed over the
next two years.
Conclusion The algorithm has good discrimination and calibration and,
after independent validation in an external cohort, could potentially be
used to identify those at highest risk of ovarian cancer to facilitate early
referral and investigation. Further research is needed to assess how
best to implement the algorithm, its cost effectiveness, and whether, on
implementation, it has any impact on health outcomes.
Introduction
Ovarian cancer is the seventh most common cancer in women
worldwide,affecting225000newpatientseachyear.
1Ofthese,
about 6700 women are in the United Kingdom, giving the UK
one of the highest rates in Europe.
2 Most women are diagnosed
withstageIIIorstageIVcancer,forwhichthefiveyearsurvival
is 20% and 6%, respectively.
3 Less than 30% of women are
diagnosed with stage I ovarian cancer, and, of these, 90% will
survive to five years. While ovarian cancer is the leading cause
of death in the UK from gynaecological malignancies, there
have been improvements in survival in the past two decades,
which might reflect earlier diagnosis and more effective
treatments.
2Ingeneralterms,theearlierthecancerisdiagnosed,
the more treatment options are available and the better the
prognosis.
As there are few established risk factors, targeted screening of
asymptomatic patients at risk of developing ovarian cancer is
unlikely to be cost effective at present (although further
information is likely to become available when the UK ovarian
cancer screening trial reports in 2015-6). The challenge
presented by ovarian cancer, therefore, is to make the correct
diagnosis as early as possible, despite the non-specific nature
of symptoms and signs.
4 This is particularly the case in primary
care, where general practitioners need to differentiate those
patientsforwhomfurtherinvestigationiswarrantedfromthose
whorequirereassuranceora“watchandwait”policy.Moreover,
primary care clinicians need to decide which patients require
urgent investigation or referral and which require routine tests
orreferral.Earlierdiagnosis,however,couldimprovewithmore
targeted investigation of symptomatic patients
5 6 and increased
public awareness of symptoms as encouraged by the National
AwarenessandEarlyDiagnosisInitiative(NAEDI).
7Ithasbeen
estimated that 10% of deaths from ovarian cancers might be
avoidable.
8Otherguidelinesandpoliciesaimtoincreaseaccess
to diagnostic investigations for general practitioners, and tools
to help assess absolute risk of different types of cancer are
needed to help ensure the right patients are investigated as well
as to optimise the use of scarce resources including abdominal
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Research
RESEARCHand transvaginal ultrasonography, computed tomography, or
magnetic resonance imaging. For ovarian cancer, the current
guidance from the National Institute for Health and Clinical
Excellence
2encouragestheuseofbloodteststomeasureCA125
concentrationforsymptomaticwomenasapreludetoultrasound
scanning,althoughthishasnotbeenvalidatedinaprimarycare
setting. CA125 concentration is raised in half the women who
have early stage ovarian cancer and 90% of those with more
advanced disease.
3
We developed and validated a risk prediction algorithm to
estimate the individualised absolute risk of having ovarian
cancer, incorporating both symptoms and other risk factors, to
help identify those at highest risk for further investigation or
referral.WeusedQResearch(alargeUKprimarycaredatabase)
to develop the risk prediction models as it contains robust data
on many of the relevant exposures and outcomes. It is also
representative of the population in which such a model is likely
to be used and has been used successfully to develop and
validate a range of prognostic models for use in primary care
9 10
as well as models designed to help earlier detection of other
cancers.
11 12
Methods
Study design and data source
We did a prospective cohort study in a large population of
primary care patients from an open cohort study using the
QResearch database (version 30). We included all practices in
England and Wales who had been using their EMIS (Egton
Medical Information System) computer system for at least a
year. We randomly allocated two thirds of practices to the
derivationdatasetandtheremainingthirdtoavalidationdataset.
Weidentifiedanopencohortofwomenaged30-84drawnfrom
patients registered with practices between 1 January 2000 and
30 September 2010. We excluded patients without a postcode
related Townsend score, patients with a history of bilateral
oophorectomyorovariancancer,andthosewitharecorded“red
flag symptom” in the 12 months before the study entry
date—that is, symptoms of loss of appetite, weight loss,
abdominal pain, abdominal distension, rectal bleeding, or
postmenopausal bleeding—that might indicate ovarian cancer.
Entry to the cohort was the latest of study start date (1 January
2000), 12 months after the patient registered with the practice,
and, for those patients with one or more red flag symptom, the
date of first recorded onset within the study period. When
patientshadnewonsetofmultiplesymptomsrecorded,theentry
date was the earliest recorded date of the new symptom in the
study period. Other symptoms were included if they occurred
within 60 days of the entry date and before the diagnosis of
ovarian cancer or the date on which the patient left, died, or the
study ended.
Clinical outcome definition
Our outcome was ovarian cancer, which we defined as incident
diagnosis of ovarian cancer during the two years after study
entry recorded either in the patient’s GP record using the
relevantUKdiagnosticReadcodesorontheirlinkedOfficefor
NationalStatistics(ONS)causeofdeathrecordwiththerelevant
ICD-9 (international classification of diseases, ninth revision)
codes (183) or ICD-10 (10th revision) diagnostic codes (C56).
The ONS data are currently linked deterministically within the
NHS clinical computer system with NHS number, postcode,
date of birth, and date of death. We used a two year period as
this represents the period of time during which existing cancers
are likely to become clinically manifest.
13 14 We assumed that
when deaths from ovarian cancer occurred within two years,
without a recorded diagnostic code in the GP record, the cancer
would have been present at the start of the two year period.
Predictor variables
Weexaminedestablishedpredictorvariables,focusingonthose
that are likely to be recorded in the patient’s electronic record
and that the patient is likely to know. We also included
symptomsthatmightheraldadiagnosisofovariancancerbased
onrecentstudies.
6 15Weincludedbothchronicriskfactors(such
as age and family history) and symptoms to determine the
absoluteriskofovariancancer.Thepredictorvariablesexamined
were:
• Currently consulting general practitioner with first onset
of loss of appetite (yes/no)
• Currently consulting general practitioner with first onset
of weight loss symptom (yes/no)
• Currently consulting general practitioner with first onset
of abdominal pain (yes/no)
• Currently consulting general practitioner with first onset
of abdominal distension (yes/no)
• Currently consulting general practitioner with first onset
of rectal bleeding (yes/no)
• Currently consulting general practitioner with first onset
of postmenopausal bleeding (yes/no)
• Recently consulted general practitioner with constipation
in past 12 months (yes/no)
• Recently consulted general practitioner with diarrhoea in
past 12 months (yes/no)
• Recently consulted general practitioner with tiredness in
past 12 months (yes/no)
• Recently consulted general practitioner with increased
urinary frequency in past 12 months (yes/no)
• Age at baseline (continuous, range 30-84)
• Body mass index (BMI) (continuous)
• Smoking status (non-smoker; ex-smoker; light (1-9
cigarettes/day); moderate (10-19 cigarettes/day); heavy
smoker (≥20 cigarettes/day)
• Alcohol use (none, trivial (<1 unit/day); light (1-2
units/day); moderate or heavy (≥3 units/day))
• Townsend deprivation score (continuous)
• Previous diagnosis of cancer apart from ovarian cancer
• Anaemia defined as recorded haemoglobin <110 g/L in
past 12 months (yes/no).
Derivation and validation of the models
Wedevelopedandvalidatedtheriskpredictionalgorithmusing
established methods.
9 10 16-20 We used multiple imputation to
replacemissingvaluesforBMI,alcoholuse,andsmokingstatus
and used these values in our main analyses.
21-24 We carried out
five imputations. We used Cox’s proportional hazards models
to estimate the coefficients for each risk factor using robust
variance estimates to allow for the clustering of patients within
general practices. We used Rubin’s rules to combine the results
across the imputed datasets.
25 We used fractional polynomials
to model non-linear risk relations with continuous variables.
26
We fitted a full model initially and retained variables if they
had a hazard ratio of <0.80 or >1.20 (for binary variables) and
were significant at the 0.01 level. We examined interactions
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RESEARCHbetween predictor variables and age and included them in the
final models if they were significant at the 0.01 level.
We used the regression coefficients for each variable from the
final model as weights, which we combined with the baseline
survivor function evaluated at two years to derive absolute risk
equationsfortwoyearsoffollow-up.
27Weestimatedthebaseline
survivor function based on zero values of centred continuous
variables, with all binary predictor values set to zero, using the
methods implemented in Stata.
We used multiple imputation in the validation cohort to replace
missingvaluesforBMI,alcohol,andsmoking.Wethenapplied
the risk equations obtained from the derivation cohort to the
validation cohort and calculated measures of discrimination.
We calculated R
2 (estimated variation in time to ovarian
cancer
28), the D statistic
29 (a measure of discrimination where
highervaluesindicatebetterdiscrimination),andtheareaunder
the receiver operating characteristic curve (Receiver Operating
Curvestatistic)attwoyears.Weassessedcalibration(comparing
the mean predicted risk at two years with the observed risk by
10th of predicted risk). The observed risks were obtained by
using Kaplan-Meier estimates evaluated at two years.
We used the validation cohort to define the thresholds for the
0.1%, 0.5%, 1%, 5%, and 10% of women at highest estimated
risk of ovarian cancer at two years. We calculated sensitivity,
specificity, and positive and negative predictive values using
thesethresholds,restrictingtheanalysestowomenwhohadthe
outcomewithintwoyearsorhadatleasttwoyearsoffollow-up.
We used all the available data on the database to maximise the
power and also generalisability of the results. We used Stata
(version 11) for all analyses.
Results
Overall study population
Overall, 564 QResearch practices in England and Wales met
our inclusion criteria and 375 were randomly assigned to the
derivation dataset with the remainder assigned to a validation
cohort. We identified 1 272 186 women aged 30-84 in the
derivation cohort. We excluded 62 392 women (4.9%) without
a recorded Townsend deprivation score, 13 748 (1.1%) with
bilateral oophorectomy, 1330 (0.1%) with a history of ovarian
cancer, and 35 993 (2.8 %) with at least one red flag symptom
recorded in the 12 months before entry to the study, leaving 1
158 723 patients for analysis
We identified 672 661 women aged 30-84 in the validation
cohort.Weexcluded35868patients(5.3%)withoutarecorded
Townsendscore,7351(1.1%)withbilateraloophorectomy,749
(0.1 %) with a history of ovarian cancer, and 19 831 (2.9%)
with at least one red flag symptom recorded in the 12 months
before study entry, leaving 608 862 patients for analysis.
The baseline characteristics of each cohort were similar (table
1⇓). As in previous studies,
9 16 30 the patterns of missing data
supported the use of multiple imputation to replace missing
values for smoking status, alcohol, and BMI (not shown,
available from the authors).
Incidence of red flag symptoms
In the derivation cohort, we identified 132 576 women with
incidentabdominalpain,5140withabdominaldistension,5920
with appetite loss, 25 274 with rectal bleeding, 18 244 with
postmenopausal bleeding, and 9081 with weight loss. Overall,
196 466 women (17%) had one red flag symptom, 2223 (0.2%)
had two, and 33 had three or more recorded symptoms.
Incidence rates of ovarian cancer
In the derivation cohort, during the two year follow-up period
we identified a total of 976 incident cases of ovarian cancer
arising from 2 025 812 person years of observation, giving a
cruderateof48per100000personyears.Therewere853cases
(87% of 976) identified using the GP record and an additional
123(13%of976)identifiedsolelyfromthelinkeddeathrecord.
In the validation cohort we identified 538 incident cases of
ovarian cancer arising from 1 065 490 person years of
observation giving a crude rate of 50 per 100 000 person years.
Therewere479cases(89%of538)identifiedwiththeGPrecord
and an additional 59 (11%) solely from the linked death record.
Predictor variables
Table 2⇓ shows the predictor variables selected for the final
model. Independent predictors were age, family history of
ovariancancer(9.8-foldhigherrisk),anaemia(2.3-foldhigher),
abdominal pain (sevenfold higher), abdominal distension
(23-fold higher), rectal bleeding (twofold higher),
postmenopausal bleeding (6.6-fold higher), appetite loss
(5.2-fold higher), and weight loss (twofold higher). The other
variables examined were not independent risk factors so were
not included in the final model. There were no significant
interactions with age.
Validation
The validation statistics (table 3⇓) showed that the risk
prediction equation explained 57.6% of the variation in time to
diagnosis. The D statistic was 2.38, and the ROC statistic was
0.84.
The figure⇓ shows the mean predicted scores and the observed
risks at two years within each 10th of predicted risk to assess
the calibration of the model in the validation cohort. Overall,
the model was well calibrated with close correspondence
between predicted and observed two year risks within each
model 10th.
Individual risk assessment and thresholds
Onepotentialuseforthisalgorithmiswithinconsultationswith
individual patients, particularly if they present with new onset
of an alarm symptom such as abdominal distension, abdominal
pain,weightloss,orappetiteloss.Theresultscouldhelpinform
thedecisiontoundertakefurtherinvestigationssuchasaCA125
blood test or abdominal ultrasonography. Some clinical
examples are shown in the box.
The algorithm could also be used for systematic risk
stratification for a population of patients aged 30-84. Software
implementingthealgorithmcouldcalculatetheriskofapatient
having an existing but as yet undiagnosed ovarian cancer based
oninformationalreadyrecordedinthepatient’selectronichealth
record. Patients at highest risk could be identified for a clinical
assessment.
As this is a new algorithm, there are no established thresholds
for defining high risk groups. We calculated a range of centiles
ofpredictedriskfromthevalidationpopulationtodefineahigh
risk group (that is, the top 0.1%, 0.5%, 1%, 5%, and 10% at
highest risk) of women. We then determined the numbers and
proportion of incident cases in the validation cohort that fell
within each category of risk.
The 90th centile defined a high risk group with a two year risk
scoreof>0.2%(table4⇓).Therewere340newcasesofovarian
cancer within this group out of 538 new cases identified in the
validation cohort, which accounted for 63.2% of all new cases
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RESEARCHClinical examples of algorithm for ovarian cancer
A 70 year old woman consulting with abdominal pain has an estimated risk of ovarian cancer of 0.6%. If she also has had anaemia in
the past year her estimated risk is 1.4%. If she also has abdominal distension her estimated risk of ovarian cancer is 28%
A 55 year old woman with a family history of ovarian cancer and consulting with loss of appetite has a 2.6% estimated risk of ovarian
cancer. If she also has abdominal distension her estimated risk is 46%. If she has loss of appetite and abdominal distension but no
family history of ovarian cancer her estimated risk of ovarian cancer is 6.1%
A 40 year old woman consulting with weight loss and abdominal pain and with anaemia in the past year has an estimated risk of ovarian
cancer of 0.3%. If she also has abdominal distension, her estimated risk is 7%
of ovarian cancer (sensitivity). The positive predictive value
with this threshold was 0.8 %. Alternatively, a threshold based
on the top 5% of risk (a two year risk score >0.5%) had a
sensitivity of 42% and a positive predictive value of 1.1%. In
contrast,thepositivepredictivevalueofsinglesymptomsranged
between 0.1% for rectal bleeding to 1.8% for abdominal
distension. The sensitivity of an approach based on single
symptoms ranged from 2% for appetite loss to 49.4% for
abdominal pain.
Discussion
Summary of key findings
We have developed and validated a new algorithm designed to
estimate the absolute risk of having existing but as yet
undiagnosed ovarian cancer based on a combination of
symptoms and simple variables such as age and family history
ofovariancancer,whichthepatientislikelytoknowandwhich
will increase the baseline absolute risk. The algorithm could be
used to assess risk at the point of care in those patients
presenting to general practitioners with these symptoms, many
ofwhicharenon-specific.Thealgorithmdoesnotactuallyresult
inadiagnosisofovariancancer,ratheritcanbeusedtoidentify
a subset of high risk women suitable for targeted investigation.
The algorithm performed well in a separate validation sample
with good discrimination and calibration. After external
validation this new algorithm could potentially be used to
identify those at highest risk of having ovarian cancer to
facilitate early referral and investigation and so help earlier
identification. Further research is needed to assess how to
implement the algorithm, its cost effectiveness, and whether,
on implementation, it has any impact on the stage of ovarian
cancer at diagnosis and subsequent survival.
Implications for clinical guidelines
Our study is topical given the recent guidelines published by
NICE in April 2011 on the recognition of ovarian cancer.
2 This
recommends carrying out tests in primary care for women
(especially those aged 50 or over) if they have any of the
following symptoms particularly more than 12 times a month:
abdominal distension; feeling full or loss of appetite, or both;
pelvic or abdominal pain; increased urinary frequency or
urgency, or both; or symptoms suggestive of irritable bowel
syndromeinthepast12months(onthebasisthatirritablebowel
syndrome rarely presents for the first time in women aged 50
and over); or unexplained weight loss, fatigue, or changes in
bowel habit. NICE guidelines recommend that women with
symptoms suggestive of ovarian cancer should have a CA125
testandiftheconcentrationis35IU/mLormore,anultrasound
scanoftheabdomenandpelvisshouldbeundertaken.Afterthe
scan a risk of malignancy score should be calculated, based on
menopausal status, CA125 concentration, and ultrasound
findings. Those with a score of 250 or more should be referred
to a specialist team. NICE also acknowledges, however, that
researchisneededtodeterminethespecificitiesandsensitivities
of the risk of malignancy score at different thresholds as well
as evidence for the performance of CA125 in a primary care
setting.
Our study lends some support to NICE guidelines, as we have
confirmedthatabdominaldistension,unintentionalweightloss,
loss of appetite, and abdominal pain all independently predict
ovarian cancer. Other symptoms such as urinary frequency,
however, are mentioned in the NICE guideline but were not
significant predictors in our study on multivariate analysis.
Similarly, we found additional symptoms such as anaemia,
postmenopausal bleeding, and rectal bleeding, which were
independentlypredictiveonmultivariateanalysis,thatwerenot
included in the NICE guideline. Importantly, our algorithm
takes better account of age than the NICE guideline, which
simply dichotomises patients into those aged under 50 or 50
andolder.Thisisrelevantastheriskofovariancancerincreases
withage.Wehavealsoquantifiedtheriskassociatedwithfamily
historyofovariancancerandincorporateditintotheunderlying
algorithm so that it is possible to calculate a woman’s absolute
risk of ovarian cancer. We have provided information on the
sensitivity, specificity, and positive and negative predictive
powers at different thresholds of risk so that this can be used
for cost effectiveness modelling, which is outside the scope of
the present study. Such modelling, along with an evaluation of
the performance of CA125 testing in symptomatic women in a
primarycaresetting,hasthepotentialtoinformfuturerevisions
of the NICE guideline.
Comparison with previous studies
Ourstudyhasgoodfacevalidityasthedirectionandmagnitude
ofthehazardratiosandpredictivevalueofindividualsymptoms
in our study are comparable with those reported elsewhere.
2 6 15
Inparticular,thesymptomthathadthelargestpositivepredictive
powerinourstudy(abdominaldistension)wasalsothestrongest
predictor in a recent study by Hamilton et al based on 39
practices in Devon over a four year period.
6 Abdominal
distension was also associated with an odds ratio of 29.2 (95%
confidence interval 16.5 to 51.8) in a recent systematic review
4
andwasthesymptomwiththehighestoddsratio.Thefrequency
of abdominal pain in patients with ovarian cancer in our study
was49%,whichissimilartothatreportedinarecentsystematic
review
4 and that reported by Hamilton et al.
6 Overall, this acts
asausefulcrossvalidationofbothstudies,whichhavedifferent
strengths. The Hamilton study was able to validate outcomes
againsthistologicalrecords,whichwasnotpossibleinourstudy.
Ourstudy,however,wasmuchlargerandnationallyratherthan
locally based and included additional variables such as age,
family history, and presence of anaemia alongside symptoms
and gives a combined individualised measure of absolute risk
of ovarian cancer. The inclusion of symptoms potentially
extends the utility of this algorithm to the point of care
consultation with a symptomatic patient as family physicians
could use it to assess the patient’s absolute baseline risk as well
as the probable increased risk from recent onset of symptoms.
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RESEARCHMethodological strengths
Key strengths of our study include size, duration of follow-up,
representativeness,andlackofselection,recall,andrespondent
bias. UK general practices have good levels of accuracy and
completeness in recording clinical diagnoses and prescribed
drugs.
31Wethinkourstudyhasgoodfacevalidityasithasbeen
conducted in the setting in which most patients in the UK are
assessed,treated,andfollowedup.Wedevelopedthealgorithm
inonecohortandvalidateditinaseparatecohortrepresentative
of the patients likely to be considered for referral and treatment.
Comparison of published discrimination statistics suggests our
model performs well (our ROC value was 0.84). Lastly, the
algorithm can be built into clinical systems and the results
generated automatically with suggestions on next steps (for
example,suitabilityforCA125testingorultrasoundscanning),
which potentially has a greater utility than a paper based flow
chart that might be difficult for busy clinicians to remember in
routine primary care.
Limitations
Limitations include a lack of formally adjudicated outcomes,
potential information bias, and missing data. Our database has
linkedcauseofdeathfromtheUKOfficeforNationalStatistics,
and our study is therefore likely to have picked up most cases
ofovariancancer,therebyminimisingascertainmentbias.While
QResearch does not currently have information on the type,
grade, and stage of ovarian cancer, it is highly unlikely that the
diagnosis would have been recorded without this being
established in the clinical setting. The QResearch database is
currently being linked to the cancer registry so that more
informationontype,grade,andstageofcanceratdiagnosiswill
be available for future analyses and refinements of this model.
Patientswhodiefromovariancancerinhospitalwillbeincluded
through the linked cause of death data. Patients diagnosed with
ovarian cancer in hospital will have the information recorded
in hospital discharge letters, which are sent to the general
practitionerandthenenteredintothepatient’selectronicrecord.
The incidence rate in our population was higher than published
national data based on cancer registries.
2 While we rely on
accuracy of information recorded by primary care physicians,
we think that the quality of information is probably good as
previousstudieshavevalidatedsimilaroutcomesandexposures
using questionnaire data and found levels of completeness and
accuracy in similar general practice databases to be good.
32 33
For example, one systematic review reported that on average
89% of diagnoses recorded on the general practice electronic
record are confirmed from other data sources.
32
Another limitation of our study is that recording of symptoms
might be less complete or less accurate than diagnostic codes
as women might not visit their general practitioner with mild
symptoms,mightnotreportallsymptomswhentheydoconsult,
or general practitioners might not record all the symptoms in
the electronic health record. The effect of this information or
recording bias could be to overinflate the hazard ratios if they
relate to more severe symptoms (such as abdominal distension)
orunderestimatethehazardratiosifpatientswiththesymptoms
don’t have them recorded. Also, the design of our study meant
it was not possible to rate severity of symptoms as in the study
by Goff et al.
15 The Goff study was designed to describe the
pattern of self reported symptoms in women with and without
ovariancancerpresentingtoprimarycareratherthantodevelop
and validate a prediction algorithm. Similarly, family history
of ovarian cancer might be under-recorded as it is not routinely
assessedandrecordedingeneralpracticerecords.Onepractical
mechanismtohelpimproveclinicalrecordingoffamilyhistory
andsymptomsforfuturestudieswouldbetointroduceelectronic
templatesintogeneralpracticesystemsthataredisplayedwhen
a “red flag” symptom is recorded in the patient’s record. The
template would then help structured data entry of other related
symptoms, including important negative findings. Over time
this would improve the accuracy and completeness of the
electronic record and hence the underlying data used for future
versions of this algorithm.
While the validation cohort was derived from practices using
thesameclinicalcomputersystem(EMIS),theywerephysically
discrete. Also, as this computer system is used in over half of
general practices on the UK, our results are likely to generalise
well. Nonetheless, it is possible that the validation has given
overoptimistic results as the practices in the validation sample
used the same computer system. A separate independent
validation study using another general practice database is
planned and hasn’t been included in the present study so that it
can be undertaken and published by an independent team.
Summary
In summary, we have developed and validated a model that can
be used to estimate the absolute risk of patients having an
existing but as yet undiagnosed ovarian cancer. The algorithm
is based on simple clinical variables that can be ascertained in
clinical practice. While the algorithm itself does not make a
diagnosis of ovarian cancer, it performed well to identify high
risk women in a separate validation sample with good
discrimination and calibration. The early diagnosis of ovarian
cancer,however,remainsachallenge.Furtherresearchisneeded
to assess how best to implement the algorithm, its cost
effectiveness,andwhether,onimplementation,ithasanyimpact
on the stage of ovarian cancer at diagnosis and subsequent
survival.
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RESEARCHWhat is already known on this topic
Ovarian cancer is the second most common gynaecological cancer and most women are diagnosed with late stage disease, which has
a poor survival rate
Earlier diagnosis could improve with more targeted investigation of symptomatic patients and increased public awareness of symptoms,
which is a major challenge given the non-specific nature of some of the symptoms
What this study adds
An algorithm based on simple clinical variables such as age, family history of ovarian cancer, anaemia, abdominal pain, abdominal
distension, rectal bleeding, postmenopausal bleeding, appetite loss, and weight loss, which the patient is likely to know or which are
routinely recorded in general practice computer systems, can estimate absolute risk of ovarian cancer in women with and without
symptoms in primary care
The algorithm could be integrated into general practice clinical computer systems and used to assess risk in women presenting with
and without symptoms
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RESEARCHTables
Table 1| Baseline characteristics of women in derivation and validation cohorts used to determine algorithm for identification of those with
ovarian cancer. Patients were free from diagnosis of ovarian cancer at baseline. Figures are numbers (percentages) unless otherwise
specified
Validation cohort (n=608 862) Derivation cohort (n=1 158 723)
50.9 (15.4) 51 (15.5) Mean (SD) age (years)
−0.2 (3.5) −0.4 (3.3) Mean (SD) Townsend score (deprivation)
512 388 (84.2) 956 594 (82.6) BMI recorded before study entry
26.2 (5.0) 26.1 (5.0) Mean (SD) BMI
Smoking status:
348 702 (57.3) 666 968 (57.6) Non-smoker
102 369 (16.8) 190 871 (16.5) Ex-smoker
14 067 (2.3) 25 634 (2.2) Current smoker (number not recorded)
33 721 (5.5) 63 092 (5.4) Light smoker (<10/day)
47 486 (7.8) 88 433 (7.6) Moderate smoker (10-19/day)
29 228 (4.8) 53 408 (4.6) Heavy smoker (≥20 day)
33 289 (5.5) 70 317 (6.1) Not recorded
Alcohol status:
176 830 (29.0) 329 078 (28.4) None
207 388 (34.1) 381 599 (32.9) Trivial (<1 unit/day)
100 966 (16.6) 196 164 (16.9) Light (1-2 units/day)
14 740 (2.4) 28 396 (2.5) Moderate or heavy (≥3 units/day)
108 938 (17.9) 223 486 (19.3) Not recorded
Medical history:
15 404 (2.5) 29 333 (2.5) Previous cancer apart from ovarian cancer
1297 (0.2) 1991 (0.2) Family history of ovarian cancer
Current symptoms:
73 674 (12.1) 132 576 (11.4) Abdominal pain
3185 (0.5) 5140 (0.4) Abdominal distension
3176 (0.5) 5920 (0.5) Appetite loss
13 988 (2.3) 25 274 (2.2) Rectal bleeding
10 285 (1.7) 18 244 (1.6) Postmenopausal bleeding
7725 (1.3) 13 858 (1.2) Weight loss
Symptoms in preceding year:
5138 (0.8) 9081 (0.8) Constipation
6858 (1.1) 12 259 (1.1) Diarrhoea
8608 (1.4) 15 265 (1.3) Tiredness
745 (0.1) 931 (0.1) Urinary frequency
130 067 (21.4) 242 535 (20.9) Haemoglobin recorded
12 894 (2.1) 23 589 (2.0) Haemoglobin <110 g/L
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RESEARCHTable 2| Adjusted hazard ratios (95% CI) for final model* for ovarian cancer in derivation cohort. Hazard ratios adjusted for all other terms
in table and for age
HR (95% CI)
9.8 (5.4 to 17.8 ) Family history of ovarian cancer†
2.3 (1.7 to 2.9 ) Haemoglobin <110 g/L in past year†
Current symptoms:
7.0 (6.1 to 8.0 ) Abdominal pain†
23.1 (18.2 to 29.4 ) Abdominal distension†
5.2 (3.4 to 7.9 ) Appetite loss†
2.0 (1.4 to 2.8 ) Rectal bleeding†
6.6 (5.1 to 8.5 ) Postmenopausal bleeding†
2.0 (1.3 to 3.1 ) Weight loss†
*Also included fractional polynomial terms for age, which were age
−0.5, age
−0.5 ln(age).
†Compared with women without this characteristic.
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RESEARCHTable 3| Validation statistics for risk prediction algorithm for ovarian cancer in validation cohort
Mean (95% CI)
57.6 (54.8 to 60.4) R
2 statistic* (%)
2.38 (2.24 to 2.51) D statistic†
0.84 (0.83 to 0.86) ROC statistic†
*Shows explained variation in time to diagnosis of ovarian cancer; higher values indicate more variation is explained.
†Measure of discrimination; higher values indicate better discrimination.
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RESEARCHTable 4| Comparison of strategies to identify women at risk of diagnosis of ovarian cancer in next two years based on validation cohort
Negative
predictive
value (%)
Positive
predictive
value (%)
Specificity
(%)
Sensitivity
(%)
True
positive*
False
positive*
False
negative* True negative*
Risk
threshold
(%) Criteria
99.9 1.1 99.8 2.0 11 983 527 470 593 NA Family history of
ovarian cancer
99.9 0.1 97.8 2.0 11 10 295 527 461 281 NA Rectal bleeding
99.9 0.6 98.3 9.1 49 7 952 489 463 624 NA Postmenopausal
bleeding
99.9 0.5 88.6 49.4 266 53 967 272 417 609 NA Abdominal pain
99.9 1.8 99.5 7.8 42 2 264 496 469 312 NA Abdominal distension
99.9 0.5 99.6 2.0 11 2 004 527 469 572 NA Appetite loss
99.9 0.4 98.9 4.1 22 5 146 516 466 430 NA Weight loss
100.0 0.5 82.9 71.9 387 80 734 151 390 842 NA Any of six above
symptoms†
100.0 0.8 90.8 63.2 340 43 594 198 427 982 0.2 Top 10% risk
99.9 1.1 95.6 42.2 227 20 857 311 450 719 0.5 Top 5% risk
99.9 2.1 99.3 13.9 75 3492 463 468 084 0.7 Top 1% risk
99.9 3.2 99.6 11.0 59 1786 479 469 790 1.4 Top 0.5% risk
99.9 5.5 99.9 3.9 21 362 517 471 214 2.3 Top 0.1% risk
NA=not applicable.
*True negative=criterion not met, does not have disease; false negative=criterion not met, does have disease; false positive=criteria met, does not have disease;
true positive=criterion met and has disease.
†This would include 17.2% of all women.
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RESEARCHFigure
Mean predicted risk and observed risk of ovarian cancer over two years by 10th of predicted risk, applying risk prediction
scores to validation cohort
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